885340-12-5 Usage
Description
1-[3-(Benzoyloxy)propyl]-2,3-dihydro-5-[(2R)-2-[[2-[2-(2,2,2-trifluoroethoxy)phenoxy]ethyl]amino]propyl]-1H-indole-7-carbonitrile ethanedioate is a complex organic compound that serves as an intermediate in the synthesis of pharmaceuticals. It is characterized by its unique molecular structure, which includes a benzoyloxypropyl group, a 2,3-dihydro-1H-indole core, and an ethanedioate (oxalate) salt form. 1-[3-(Benzoyloxy)propyl]-2,3-dihydro-5-[(2R)-2-[[2-[2-(2,2,2-trifluoroethoxy)phenoxy]ethyl]amino]propyl]-1H-indole-7-carbonitrile ethanedioate plays a crucial role in the development of medications targeting specific receptors in the human body.
Uses
Used in Pharmaceutical Industry:
1-[3-(Benzoyloxy)propyl]-2,3-dihydro-5-[(2R)-2-[[2-[2-(2,2,2-trifluoroethoxy)phenoxy]ethyl]amino]propyl]-1H-indole-7-carbonitrile ethanedioate is used as a key intermediate in the synthesis of silodosin, an α1a-adrenoceptor antagonist. Silodosin is primarily utilized in the treatment of benign prostatic hypertrophy (BPH), a condition characterized by the enlargement of the prostate gland, leading to urinary symptoms and discomfort. 1-[3-(Benzoyloxy)propyl]-2,3-dihydro-5-[(2R)-2-[[2-[2-(2,2,2-trifluoroethoxy)phenoxy]ethyl]amino]propyl]-1H-indole-7-carbonitrile ethanedioate's role in the synthesis process is essential for producing a medication that can effectively manage BPH and improve patients' quality of life.
As a silodosin intermediate, 1-[3-(Benzoyloxy)propyl]-2,3-dihydro-5-[(2R)-2-[[2-[2-(2,2,2-trifluoroethoxy)phenoxy]ethyl]amino]propyl]-1H-indole-7-carbonitrile ethanedioate contributes to the development of a medication that offers a targeted approach to treating BPH. By antagonizing the α1a-adrenoceptor, silodosin helps relax the muscles in the prostate and bladder neck, thereby alleviating urinary symptoms associated with the condition. 1-[3-(Benzoyloxy)propyl]-2,3-dihydro-5-[(2R)-2-[[2-[2-(2,2,2-trifluoroethoxy)phenoxy]ethyl]amino]propyl]-1H-indole-7-carbonitrile ethanedioate's application in the pharmaceutical industry highlights its importance in creating effective treatments for patients suffering from benign prostatic hypertrophy.
Check Digit Verification of cas no
The CAS Registry Mumber 885340-12-5 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 8,8,5,3,4 and 0 respectively; the second part has 2 digits, 1 and 2 respectively.
Calculate Digit Verification of CAS Registry Number 885340-12:
(8*8)+(7*8)+(6*5)+(5*3)+(4*4)+(3*0)+(2*1)+(1*2)=185
185 % 10 = 5
So 885340-12-5 is a valid CAS Registry Number.
885340-12-5Relevant articles and documents
Improved Preparation of Silodosin
Liu, Hui,Lv, Fei,Liu, Yuan
, p. 287 - 293 (2019/05/17)
-
INDOLINE COMPOUND AND PROCESS FOR PRODUCING THE SAME
-
Page/Page column 11-12, (2010/11/08)
A process for industrially producing silodosin, which is a therapeutic agent for urination disorders accompanying prostatic hypertrophy. The process for silodosin production is characterized by mixing 3-{7-cyano-5-[(2R)-2-({2-[2-(2,2,2-trifluoroethoxy)phenoxy]ethyl}amino)propyl]-2,3-dihydro-1H-indol-1-yl}propyl benzoate with oxalic acid to yield an oxalate, subsequently hydrolyzing the oxalate to yield 1-(3-hydroxypropyl)-5-[(2R)-2-({2-[2-(2,2,2-trifluoro-ethoxy)phenoxy]ethyl}amino)propyl]-2,3-dihydro-1H-indole-7-carbonitrile, and hydrolyzing it. Also provided is an intermediate for use in the production.